PharmAust (ASX:PAA) escalates dosage of third patient cohort in MND/ALS trial
PharmAust (ASX:PAA) has announced that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of MPL in MND and ALS.
Be the first with the news that moves the market
Subscribe Be the first with the news that moves the market
PharmAust (PAA) announces that all 12 patients in ...
Read More
Other Stories in Business
- Results similar to 'will-jinxin-fertility-01951-hk-preempt-the-market-upon-policy-certainty--performance-elasticity'
- Explained: All About National Blockchain Tech Stack, Vishvasya
- ChargePoint Holdings: Elevated Cash Usage, Delayed Profitability Targets
- CBA share price: some easy ways to research it
- National strategy for Prevention of Unintentional Injury launched
- Road safety: India complies with only 3 of 12 UN targets
- K.P. Singh’s Post-Covid Realty Heights
- Tolins Tyres Sets Price Band For Rs 230-Crore IPO, Issue Opens Sept. 9
- JSW Cement IPO Put On Hold By SEBI
